NASDAQ - Horizon Therapeutics Public Limited Company

График котировок Horizon Therapeutics Public Limited Company


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/E 52.22
P/S 9.62
P/BV 5.2
EV/EBITDA 34.88
EBITDA 0.5545
Цена ао 94.51

Все параметры ⇨

Оценка

Недооценка

Название Значение Оценка
P/S 9.62 1
P/BV 5.2 1
P/E 52.22 1
EV/EBITDA 34.88 3

Эффективность

Название Значение Оценка
ROA, % 6.31 2
ROE, % 12.55 4

Дивиденды

Название Значение Оценка
Div yield, % 0
DSI 0 0

Долг

Название Значение Оценка
Долг/EBITDA 0

Импульс роста

Название Значение Оценка
Рост прибыли, % 373.25 10
Рост цены акции, % 92.06 10
Рост дивидендов, % 0 0

Инсайдерская торговля

Дата сделки Дата раскрытия Инсайдер Тип Цена Объем Количество Доля до, % Доля после, % Документ
05.11.2020 06.11.2020 Kent Jeff
See remarks
Продажа 78.94 3 784 700.00 47944 0 -0.03 ссылка
06.11.2020 06.11.2020 Camardo Daniel A.
EVP and President, U.S.
Продажа 76.76 268 660.00 3500 0 0 ссылка
05.11.2020 06.11.2020 MOZE BARRY
EVP, Chief Admin. Officer
Продажа 78.93 6 117 080.00 77500 0 -0.04 ссылка

Основные владельцы

Institutions Объем Доля, %
Sabrient Systems 94877 0.04
Hennion & Walsh, Inc 400 0
Principal Global Investors, LLC 1136526 0.51
Janus Capital Management LLC 13982253 6.34
Allianz Global Investors GmbH 1264092 0.57
Fidelity Management & Research Company LLC 21277027 9.64
Bellevue Asset Management AG 321600 0.15
Paulson & Company Inc 6691439 3.03
Allianz Global Investors U.S. LLC 1478161 0.67
Pacific Life Fund Advisors LLC (PLFA) 645777 0.29
TreeTop Asset Management SA 177590 0.08
BlackRock Fund Advisors 10775170 4.88
Invesco Advisers, Inc. 1928813 0.87
Allianz Global Investors 403068 0.18
Eversept Partners, LLC 607757 0.28
Voya Investments, LLC 2402727 1.09
Liontrust Investment Management Limited 257242 0.12
International Biotechnology Trust PLC 389000 0.18
FIL Fund Management Limited 246330 0.11
Kopp Family Office, LLC 427465 0.19
Hennion & Walsh, Inc 400 0
Fidelity Management & Research Company LLC 16620054 7.53
Paulson & Company Inc 6691439 3.03
Invesco Capital Management LLC 961963 0.44
Boston Company Asset Mgmt, LLC 204885 0.09
Financial Trust Asset Management 1058 0
AMG Funds LLC 152694 0.07
Security Investors, LLC 166461 0.08

Содержится в ETF

ETF Доля, % Доходность за год, % Дивиденды, %
Vanguard Small Cap ETF 0.32 41.94 1.02
Vanguard Small Cap Growth ETF 0.69 43.33 0.41
iShares Nasdaq Biotechnology ETF 1.64 31.26 0.19
iShares U.S. Pharmaceuticals ETF 5.78 21.89 1.20
SPDR S&P Pharmaceuticals ETF 4.92 26.40 0.46
Principal Healthcare Innovators Index ETF 2.44 61.80 0.34
First Trust Nasdaq Pharmaceuticals ETF 4.6 19.58 0.80
SoFi Next 500 ETF 0.99 39.16 1.07
Direxion Daily Pharmaceutical & Medical Bull 3X Shares 5 37.25 0.98
American Century Mid Cap Growth Impact 3.6 0.45
JPMorgan BetaBuilders U.S. Mid Cap Equity ETF 0.6 0.64
ProShares Ultra Nasdaq Biotechnology 1.39 49.35 0.95
iShares Russell 2500 ETF 0.29 45.15 1.20
iShares Edge MSCI Multifactor USA Mid-Cap ETF 1.58 32.25 1.16
First Trust Health Care AlphaDEX Fund 2 31.84 0.61
Invesco Dynamic Pharmaceuticals ETF 3.5 29.30 0.70
Goldman Sachs Hedge Industry VIP ETF 2.27 55.09 0.12
Invesco Russell 1000 Low Beta Equal Weight ETF 0.34 11.09 2.39

Похожие компании

Описание Horizon Therapeutics Public Limited Company

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.